【摘 要】
：
Objective: Glioma is a highly invasive tumor, frequently disposed in essential areas of the brain, which makes its surgical excision extremely difficult; meanwh
【机 构】
：
Institute of Cytology and Genetics SB RAS,Novosibirsk 630090,Russia;A.I.Evdokimov Moscow State Unive
论文部分内容阅读
Objective: Glioma is a highly invasive tumor, frequently disposed in essential areas of the brain, which makes its surgical excision extremely difficult; meanwhile adjuvant therapy remains quite ineffective. Methods: In the current report, a new therapeutic approach in curing malignant neoplasms has been performed on the U87 human glioblastoma model. This approach, termed “Karanahan”, is aimed at the eradication of cancer stem cells (CSCs), which were recently shown to be capable of internalizing fragments of extracellular double-stranded DNA. After being internalized, these fragments interfere in the process of repairing interstrand cross-links caused by exposure to appropriate cytostatics, and such an interference results either in elimination of CSCs or in the loss of their tumorigenic potency. Implementation of the approach requires a scheduled administration of cytostatic and complex composite double-stranded DNA preparation. Results: U87 cells treated in vitro in accordance with the Karanahan approach completely lost their tumorigenicity and produced no grafts upon intracerebral transplantation into immunodeficient mice. In SCID mice with developed subcutaneous grafts, the treatment resulted in reliable slowing down of tumor growth rate (P < 0.05). In the experiment with intracerebral transplantation of U87 cells followed by surgical excision of the developed graft and subsequent therapeutic treatment, the Karanahan approach was shown to reliably slow down the tumor growth rate and increase the median survival of the mice twofold relative to the control. Conclusions: The effectiveness of the Karanahan approach has been demonstrated both in vitro and in vivo in treating developed subcutaneous grafts as well as orthotopic grafts after surgical excision of the tumor.
其他文献
目的:探究丁苯酞联合单唾液酸四己糖神经节苷脂钠治疗重症缺血性脑血管病(ICVD)的临床疗效。方法:选取2018年5月~2019年5月本院收治的230例重症ICVD患者作为研究对象,按照随机数字表法将其分为观察组和对照组,各115例。对照组予以丁苯酞软胶囊治疗,观察组在对照组基础上予以单唾液酸四己糖神经节苷脂钠注射液治疗。比较两组临床疗效、治疗前和治疗后简易智力状态检查量表(MMSE)评分、美国国立卫生研究院卒中量表(NIHSS)评分、Fugl-Meyer评定量表(FMA)评分、血液流变学指标、生活质量(Q
目的:通过对北京市某社区医疗机构就诊患者开展问卷调查,了解患者选择到社区医院就诊的现状及原因,及其对社区医疗机构开展药学服务的认知度,探索社区药师开展药学服务与慢病管理的发展方向,提升专业能力与社会认可度。方法:采用问卷网相关软件,由社区药师自行设计调查问卷,对患者随机发放并回收该调查问卷,使用Excel软件对结果进行统计分析。结果:随机发放调查问卷431份,均有效回收问卷(有效回收率100%)。40.37%调研对象表示从未得到过社区医疗机构的药学服务,不愿选择社区医疗机构就诊的理由主要包括:担心诊疗设备
目的:分析他克莫司血药浓度的影响因素,为临床合理用药提供参考。方法:以现有国内外科研资料为基础进行分析归纳总结。结果:他克莫司血药浓度与患者年龄、性别、病理生理状态、联合用药、CYP3A4等基因的多态性有关。结论:建议临床应用他克莫司时,根据患者实际情况,结合临床实践、基因多态性、血药浓度,实施个体化精准用药,以保证合理用药的安全性和有效性。
目的:研究尿石清合剂的水提醇沉工艺,优选最佳提取条件。方法:采用L 9(34)正交试验筛选提取工艺;以加水量(A)、浸泡时间(B)、提取时间(C)、提取次数(D)作为考察因素,以总固物重量及栀子苷含量为考察指标优选尿石清合剂的水提工艺;以相对密度(A)、含醇量(B)、醇沉时间(C)为考察因素优选尿石清合剂的醇沉工艺。结果:尿石清合剂最佳提取条件为:加12倍量水,浸泡1 h,提取2次,每次2 h,醇沉浓度为60%,药液初始相对密度1.10,醇沉时间为24 h。结论:优选得到的尿石清合剂的提取工艺可行,质量稳
Objective: To compare the efficacy and safety of hyperthermic intravesical chemotherapy (HIVEC) and intravesical chemotherapy (IVEC) in patients with intermedia
目的:评价复方脑肽节苷脂注射液治疗急性缺血性脑卒中(ischemic stroke,IS)的安全性和有效性。方法:选择2017年11月~2018年11月河北医科大学附属第二医院等6家医院收治的急性IS患者388例为研究对象,在常规治疗的基础上,根据合并用药不同分为试验组(复方脑肽节苷脂注射液+常规治疗)191例、对照组(其他神经节苷脂类药物+常规治疗)100例、空白组(常规治疗)97例。观察治疗前后各组美国国立卫生研究院脑卒中量表(NIHSS)评分及改良Rankin量表(mRS)评估结果,根据NIHSS评
HELLP综合征是以溶血、肝酶升高及血小板减少为特点的严重妊娠并发症,常危及母儿生命。临床上对HELLP综合征早期识别,及时诊断以及规范处理十分重要。本文就HELLP综合征的发病机制、诊断、治疗以及相关研究进展进行讨论。
目的:建立阿司匹林中对羟基苯甲酸杂质测定的不确定度评定方法,探讨影响测定的不确定度分量。方法:依据欧洲药品质量管理局(EDQM)能力验证文件对《欧洲药典》阿司匹林标准中的对羟基苯甲酸杂质含量测定的全过程分析,建立不确定度的数学模型,分析测量不确定度的来源并对各分量进行量化分析和评估,合成标准测量不确定度,给出标准不确定度报告。结果:阿司匹林中的对羟基苯甲酸含量为0.250%,其标准不确定度为0.002%,测量结果表示为(0.250±0.002)%。结论:建立了《欧洲药典》阿司匹林标准中的对羟基苯甲酸杂质含
Objective:Glioblastoma(GBM)is the most prevalent and aggressive adult primary cancer in the central nervous system.Therapeutic approaches for GBM treatment are under intense investigation,including the use of emerging immunotherapies.Here,we propose an al
子痫前期的预防策略包括预防发生及预防发展,尤其防止发展成为重症。预防子痫前期的发生包括初级预防和对母体基础疾病的筛查与诊治,更强调对育龄妇女在孕前进行相关知识的教育;还有妊娠期间的管理,包括预警和早发现、早诊断,更重要的是早干预和早处理。在妊娠的任何时段,预防子痫前期发生是一个层面,预防发展到重度子痫前期是一个层面,避免母儿死亡又是一个层面,本文层层解析。